01/29/2026
🌟 Research Opportunity: Mount Sinai Long-COVID Study 🌟
Mount Sinai Hospital (NY) has selected lumbrokinase (Boluoke®) for a clinical trial investigating its role in Long-COVID, with relevance to related post-infectious conditions including:
• Long-COVID
• Post-Treatment Lyme Disease Syndrome (Chronic Lyme)
• Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)
This study is funded by the PolyBio Research Foundation and is based on growing scientific interest in fibrin, microcirculation, and post-infectious illness mechanisms.
⏳ Important: Patient enrollment is expected to close in Spring 2026.
🔍 Learn more about the study design:
https://ctv.veeva.com/study/lumbrokinase-for-long-covid-clinical-trial
💡 Why lumbrokinase was selected for this research:
https://polybio.org/projects/lumbrokinase-longcovid-me-cfs-clinical-trial/
📩 For patients interested in enrolling (eligibility, email, and phone contact):
https://www.mountsinai.org/clinical-trials/lumbrokinase-for-adults-with-long-covid-posttreatment-lyme-disease-syndrome-and-myalgic-encephalomyelitischronic-fatigue-syndrome
Please consider sharing to help reach patients who may be seeking research opportunities.
